Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 45; no. 2; p. 193
• Main Authors: Tebas, Pablo, Zhang, Jiameng, Yarasheski, Kevin, Evans, Scott, Fischl, Margaret A, Shevitz, Abby, Feinberg, Judith, Collier, Ann C, Shikuma, Cecilia, Brizz, Barbara, Sattler, Fred
• Format: Journal Article
• Language: English
• Published: United States 01.06.2007
• Subjects: Adult; Alkynes; Anti-HIV Agents - adverse effects; Anti-HIV Agents - therapeutic use; Benzoxazines - adverse effects; Benzoxazines - therapeutic use; Body Fat Distribution; Cyclopropanes; Female; HIV Infections - drug therapy; HIV-Associated Lipodystrophy Syndrome - chemically induced; Humans; Lopinavir; Male; Pyrimidinones - adverse effects; Pyrimidinones - therapeutic use; Ritonavir - adverse effects; Ritonavir - therapeutic use; Time Factors

Subcutaneous limb fat loss continues to be one the most troubling side effects of long-term antiretroviral regimens. Nucleoside analogues and protease inhibitors (PIs) have been linked to the development of this complication. We evaluated the effects of nucleoside-sparing and PI-sparing regimens on...